DeepMed Research

Corcept Therapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 352

Market Cap: $3.6B

Website

Clinical Trials

Single Dose Absorption, Distribution, Metabolism, and Excretion Study of [14C]-CORT113176 in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: [14C]-CORT113176

First Posted Date: 2021-08-04

Last Posted Date: 2021-11-24

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 6

Registration Number: NCT04990310

Locations: 🇬🇧
Site 01, Ruddington, Nottingham, United Kingdom

T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Relacorilant
Drug: Placebo to relacorilant
Drug: Moxifloxacin

First Posted Date: 2021-03-12

Last Posted Date: 2021-09-14

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 36

Registration Number: NCT04795479

Locations: 🇺🇸
Single Site, Springfield, Missouri, United States

Single and Multiple Dose Study of Miricorilant (CORT118335) Tablet Formulations in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Miricorilant 150 mg tablets
Drug: Miricorilant 300 mg tablets
Drug: Placebo 150 mg tablets

First Posted Date: 2020-12-17

Last Posted Date: 2020-12-17

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 36

Registration Number: NCT04672499

Locations: 🇬🇧
Quotient Sciences, Ruddington, Nottingham, United Kingdom

Single and Multiple Ascending Dose Study of CORT125329 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: CORT125329 lipid capsule formulation
Drug: Placebo
Drug: Prednisone

First Posted Date: 2020-12-17

Last Posted Date: 2022-02-09

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 115

Registration Number: NCT04672512

Locations: 🇬🇧
Quotient Sciences, Ruddington, Nottingham, United Kingdom

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)

Phase 2

Completed

Conditions: Antipsychotic-induced Weight Gain (AIWG)

Interventions: Drug: Miricorlilant
Drug: Placebo

First Posted Date: 2020-08-24

Last Posted Date: 2024-06-13

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 150

Registration Number: NCT04524403

Locations: 🇺🇸
Site # 240, Chicago, Illinois, United States
🇺🇸
Site #166, Philadelphia, Pennsylvania, United States
🇺🇸
Site #143, Bentonville, Arkansas, United States

and more 33 locations

Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)

Phase 1

Completed

Conditions: Adrenocortical Carcinoma

Interventions: Drug: Relacorilant
Drug: Pembrolizumab

First Posted Date: 2020-05-04

Last Posted Date: 2024-02-23

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 15

Registration Number: NCT04373265

Locations: 🇺🇸
Site #183, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Site #030 Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Site #150, Stanford Cancer Center, Stanford, California, United States

and more 3 locations

Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Phase 3

Terminated

Conditions: Metastatic Pancreatic Ductal Adenocarcinoma

Interventions: Drug: Relacorilant, 100 mg and 25 mg
Drug: Nab-paclitaxel

First Posted Date: 2020-04-01

Last Posted Date: 2023-11-18

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 43

Registration Number: NCT04329949

Locations: 🇺🇸
Site #186, Toledo, Ohio, United States
🇺🇸
Site #009, Atlanta, Georgia, United States
🇺🇸
Site #058, Detroit, Michigan, United States

and more 15 locations

Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas

Phase 3

Completed

Conditions: Hypercortisolism

Interventions: Drug: relacorilant
Other: Placebo

First Posted Date: 2020-03-16

Last Posted Date: 2024-11-19

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 137

Registration Number: NCT04308590

Locations: 🇺🇸
Site 21, Columbus, Ohio, United States
🇺🇸
Site 27, Birmingham, Alabama, United States
🇺🇸
Site 17, Stanford, California, United States

and more 42 locations

Single and Multiple Ascending Dose Study of CORT113176 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Adults

Interventions: Drug: CORT113176 Lipid Capsule Formulation
Drug: Placebo matching CORT113176 Lipid Capsule Formulation
Drug: Prednisone

First Posted Date: 2020-01-30

Last Posted Date: 2022-02-01

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 110

Registration Number: NCT04249323

Locations: 🇬🇧
Quotient Sciences, Ruddington, Nottingham, United Kingdom

Absolute Bioavailability and Metabolism Study of CORT118335 in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: CORT118335 Oral
Drug: 14C-CORT118335 oral
Drug: 14C-CORT118335 intravenous

First Posted Date: 2019-03-18

Last Posted Date: 2019-06-11

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 12

Registration Number: NCT03878264

Locations: 🇬🇧
Quotient Sciences, Ruddington, Nottingham, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy